The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care 87 million new gonorrhea infections ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products, today announced the presentation of data on ETX2514 at IDWeek ...
In financial distress last May, AstraZeneca spinout Entasis Therapeutics sold out to holding company Innoviva for $113 million. A year later—to the day—Innoviva’s subsidiary has scored its first FDA ...
WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced initiation ...
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks ...
Entasis Therapeutics Holdings Inc. ETTX announced that it has signed a definitive merger agreement with Innoviva, Inc. INVA, wherein the latter will acquire all the outstanding shares it does not own ...
WALTHAM, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
WALTHAM, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel ...
Benzinga spoke with Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) CEO Manos Perros, Ph.D. for the latest news and updates in the company's pathogen-targeted antimicrobial pipeline. Benzinga: In late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results